Indaptus Therapeutics Inc
Indaptus Therapeutics Inc logo
INDP

Indaptus Therapeutics Inc (INDP)

$1.671.14%

Market is closed
– opens on 8 PM, 30 Jan 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.67
Day's Range
$1.7464
$1.25
52-Week Range
$5.47
1 month return12.84%
3 month return8.74%
1 year return66.53%
5 year return99.66%

Insights on Indaptus Therapeutics Inc

  • Vs Vertex Pharmaceuticals, Inc.

    In the last 1 year, Vertex Pharmaceuticals, Inc. has given 32.3% return, outperforming this stock by 95.9%

  • Vs Moderna Inc

    In the last 3 years, Moderna Inc has given 38.3% return, outperforming this stock by 134.3%

Analyst Recommendation

based on 7 analysts ratings

Buy
85%
Buy
14%
Hold
0%
Sell

Based on 7 Wall street analysts offering stock ratings for Indaptus Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 678.44%

Current

$1.67

Target

$13.0

Recommendation Trend

Based on 7 analyst

Current1M Ago3M Ago
Buy
6
1
7
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization14.0M
Book Value$3.34
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.85
Wall Street Target Price13.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)0.52
Enterprise Value-13986721
Enterprise Value/Revenue0.0
Enterprise Value/Ebitda1.0

Technicals

50 Day MA1.69
200 Day MA2.35

Institutional Holdings

Vanguard Group Inc

2.98%

Investment House LLC

1.14%

Strategy Asset Managers LLC

0.66%

Geode Capital Management, LLC

0.6%

Stratos Wealth Partners, LTD

0.32%

Vivaldi Capital Management, LLC

0.29%

Company Information

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical oncology candidate, Decoy20, and is currently completing other IND enabling studies.
OrganizationIndaptus Therapeutics Inc
Employees5
CEOMr. Jeffrey A. Meckler
IndustryHealthcare

Discover more

Frequently Asked Questions

What is Indaptus Therapeutics Inc share price today?

Can Indians buy Indaptus Therapeutics Inc shares?

How can I buy Indaptus Therapeutics Inc shares from India?

Can Fractional shares of Indaptus Therapeutics Inc be purchased?

What are the documents required to start investing in Indaptus Therapeutics Inc stocks?

What are today’s High and Low prices of Indaptus Therapeutics Inc?

What are today’s traded volumes of Indaptus Therapeutics Inc?

What is today’s market capitalisation of Indaptus Therapeutics Inc?

What is the 52 Week High and Low Range of Indaptus Therapeutics Inc?

How much percentage Indaptus Therapeutics Inc is down from its 52 Week High?

How much percentage Indaptus Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Indaptus Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Indaptus Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*